Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made with six new treatments made available since the creation of DNDi, in 2003. However, major breakthroughs are still needed to treat neglected patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.


DNDi and MSF Access Campaign Directors answer questions on Reddit AMA

Bernard Pécoul and Manica Balasegaram answered questions on global health R&D funding on a PLOS Reddit Science AMA. More

DNDi hands over malaria programme to MMV

MMV and DNDi have agreed that the ASAQ and ASMQ products developed by DNDi and its partners will now be managed by the MMV Access and Product Management team. More

NTD Drug Discovery Booster

The NTD Drug Discovery Booster aims to speed up and cut the cost of finding new treatments for Leishmaniasis and Chagas Disease. The project brings together DNDi, Eisai, Shionogi, Takeda Pharmaceutical, and AstraZeneca. More

Close-up on Paediatric HIV

About 190’000 children are living with HIV in Kenya. See how this mother of an HIV-positive child struggles with the current recommended drugs, such as syrups that require refrigeration and taste awful. More

DNDi Brochure

To learn more about DNDi's activities and patients download our short Presentation Brochure! More



June 14-17, 2015
Medtrop 2015
Doenças tropicais: do ensino e pesquisa aos serviços de saúde
Ceará, Brazil
DNDi presented at sessions on Chagas disease and leishmaniasis.

July 17-18, 2015
2nd International HIV/Viral Hepatitis Co-­Infection Meeting
IAS 2015 affiliated event
Vancouver, Canada
DNDi's Head of Paediatric HIV Programme will be participating in a panel on public health advocacy and access to HCV therapy.

See all events



DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more


Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License